Overview Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506. Status: Recruiting Trial end date: 2022-01-31 Target enrollment: Participant gender: Summary Phase 3 study to evaluate the effiacay and safety of YYC506 Phase: Phase 3 Details Lead Sponsor: Yooyoung Pharmaceutical Co., Ltd.